Central administration of FMRFamide produces antipsychotic-like effects in rodents

Neuropeptides

Volumn 31, Issue 4, 1997, Pages 319-322

  Muthal, A V ^a,b   Mandhane, S N ^a   Chopde, C T ^a  

^a RTM NAGPUR UNIVERSITY   (India)

^b A Shivsagar Estate   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PHENYLALANYLMETHIONYLARGINYLPHENYLALANINAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

ANIMALIA; RODENTIA;

EID: 0030761336     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90065-2     Document Type: Article

References (26)

1. Price D A, Greenberg M J. Structure of molluscan cardioexcitatory neuropeptide. Science 1977; 197: 670-671.
2. Triepel J, Grimmelikhuijzen C J P. A critical examination of the occurrence of FMRFamide immunoreactivity in the brain of guinea pig and rat. Histochemistry 1984; 80: 63-71.
3. Raffa R B. The action of FMRFamide (Phe-Met-Arg-Phe-NH2) and related peptides on mammals. Peptides 1988; 9: 915-922.
4. Muthal A V, Chopde C T. Neuropeptide FMRFamide induces hypoglycemia in rats. Gurr Sci 1993; 65: 718-719.
5. Muthal A V, Chopde C T. Stimulation of gastric acid secretion by central administration of FMRFamide in rats. Indian J Med Res 1993; 98: 185-187.
6. Muthal A V, Chopde C T. Effect of neuropeptide FMRFamide on morphine and amphetamine stimulated locomotor activity. Indian J Pharmacol 1993; 25: 167-169.
7. 2 like immunoreactivity. Proc Natl Acad Sci USA 1984; 81: 5002-5005.
8. Muthal A V, Chopde C T. Effect of neuropeptide FMRFamide on immobile behavior in rats. Indian J Exp Biol 1995; 33: 182-185.
9. Muthal A V, Chopde C T. Anxiolytic effect of neuropeptide FMRFamide in rats. Neuropeptides 1994; 27: 105-108.
10. Robert J J, Orosco M, Rouch, C, Jacquot C, Cohen Y. Unexpected responses of the 'cafeteria' rat to the peptide FMRFamide. Pharmacol Biochem Behav 1989; 34: 341-344.
11. Raffa R B, Connelly C D. Supraspinal antinociception produced by (D-Met2)-FMRFamide in mice. Neuropeptides 1992; 3: 195-203.
12. Malin D H, Payza K, Lake J R et al. Enhanced antiopiate activity in peptidomimetics of FMRFamide containing Z-2,3-methanomethionine. Peptides 1993; 1: 47-51.
13. Pickar D, Vartanian F, Bunney W E. Short term naloxone administration in schizophrenic and manic patients. A WHO collaborative study. Arch Gen Psychiatry 1982; 39: 313-319.
14. Broccardo M, Importa G. Cross tolerance between dermorphine and morphine to analgesia and catalepsy in rats. Peptides 1985; 6 Suppl 3: 165-167.
15. Meisenberg G, Simmons W H. Amastatin potentiates the behavioral effects of vasopressin and oxytocin in mice. Peptides 1984; 5: 535-539.
16. Meltzer H Y. In: Alport M, ed. Controversies in schizophrenia: changes and constancy. New York: Guilford Press 1985: 1110-1136.
17. O'Donohue T L, Bishop J F, Chronwall B M, Groome J, Watson W H. Characterization and distribution of FMRFamide immunoreactivity in rat central nervous system. Peptides 1984; 5: 563-568.
18. Paxinos G, Watson C A. A Stereotaxic Atlas of the Rat Brain. New York: Academic Press. 1983: 1-13.
19. Moore NA, Tye N C, Axton M S, Risius F C. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545-551.
20. Neal-Beliveau B S, Joyce J N, Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993; 265: 207-216.
21. 2 receptor activation. Psychopharmacology 1988; 94: 263-266.
22. Amt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982; 51: 321-329.
23. Creese I, Burt D R, Snyder S H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
24. Hippius H. The history of clozapine. Psychopharmacology 1989; 99: S3-S5.
25. Ki values. J Pharmacol Exp Ther 1989; 251: 238-246.
26. Meltzer H Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18-S27.